Oliver Tracie's Form 4 filing
Arrowhead Pharmaceuticals, Inc. (ARWR) · filed Jan 8, 2024
- Accession no.
- 0001628280-24-000867
- Filed
- Jan 8, 2024
- Trade date
- Jan 4-5, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $2.51K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Oliver TracieCIK 0001935706 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 4, 2024 | Common Stock | AGrant or awardAcquired | +75,000 | $0.00 | $0 | 136,575 | Direct | |
| Jan 5, 2024 | Common Stock | SSaleDisposed | −74 | $33.89 | −$2,507.86 | 136,501 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.